Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 2
2018 4
2019 9
2020 8
2021 9
2022 9
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
Martínez JL, Lemus N, Lai TY, Mishra M, González-Domínguez I, Puente-Massaguer E, Loganathan M, Francis B, Samanovic MI, Krammer F, Mulligan MJ, Simon V, Palese P, Sun W. Martínez JL, et al. Among authors: sun w. Vaccine. 2024 Apr 15:S0264-410X(24)00451-1. doi: 10.1016/j.vaccine.2024.04.037. Online ahead of print. Vaccine. 2024. PMID: 38627145 Free article.
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
Clark J, Hoxie I, Adelsberg DC, Sapse IA, Andreata-Santos R, Yong JS, Amanat F, Tcheou J, Raskin A, Singh G, González-Domínguez I, Edgar JE, Bournazos S, Sun W, Carreño JM, Simon V, Ellebedy AH, Bajic G, Krammer F. Clark J, et al. Among authors: sun w. bioRxiv [Preprint]. 2024 Mar 1:2024.02.28.582613. doi: 10.1101/2024.02.28.582613. bioRxiv. 2024. PMID: 38464151 Free PMC article. Preprint.
Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.
Puente-Massaguer E, Vasilev K, Beyer A, Loganathan M, Francis B, Scherm MJ, Arunkumar GA, González-Domínguez I, Zhu X, Wilson IA, Coughlan L, Sun W, Palese P, Krammer F. Puente-Massaguer E, et al. Among authors: sun w. Sci Adv. 2023 Sep 15;9(37):eadi4753. doi: 10.1126/sciadv.adi4753. Epub 2023 Sep 13. Sci Adv. 2023. PMID: 37703367 Free PMC article.
Group 1 and group 2 hemagglutinin stalk antibody response according to age.
Sánchez-de Prada L, Sanz-Muñoz I, Sun W, Palese P, Ortiz de Lejarazu R, Eiros JM, García-Sastre A, Aydillo T. Sánchez-de Prada L, et al. Among authors: sun w. Front Immunol. 2023 May 29;14:1194073. doi: 10.3389/fimmu.2023.1194073. eCollection 2023. Front Immunol. 2023. PMID: 37313413 Free PMC article.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Ponce-de-León S, et al. Among authors: sun w. NPJ Vaccines. 2023 May 10;8(1):67. doi: 10.1038/s41541-023-00662-6. NPJ Vaccines. 2023. PMID: 37164959 Free PMC article.
51 results